Exicure, Inc. - Common Stock (XCUR)
5.8900
+0.3400 (6.13%)
NASDAQ · Last Trade: Jun 29th, 4:54 PM EDT
Via Benzinga · June 27, 2025
Via Benzinga · April 17, 2025
Via Benzinga · March 18, 2025
Via Benzinga · March 13, 2025

Via Benzinga · February 7, 2025

GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.
Via Stocktwits · January 23, 2025

Via Benzinga · January 23, 2025

Via Benzinga · January 15, 2025

Via Benzinga · January 7, 2025

Via Benzinga · December 4, 2024

Via Benzinga · December 4, 2024

Via Benzinga · November 25, 2024

Via Benzinga · November 25, 2024

Via Benzinga · November 22, 2024

Via Benzinga · November 22, 2024

Via Benzinga · November 20, 2024

Via Benzinga · October 31, 2024

Via Benzinga · October 15, 2024

Via Benzinga · October 9, 2024

Via Benzinga · October 8, 2024

Via Benzinga · September 20, 2024

Via Benzinga · September 19, 2024

Via Benzinga · September 19, 2024